Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
AviadoBio logo — A revolution in gene therapy for neurodegenerative disorders...

AviadoBio

A revolution in gene therapy for neurodegenerative disorders.

Founded 2019 United Kingdom London, United Kingdom 73 employees Corporate Round Total: $90.60M Biotechnology, Health Care

General Information

Company Name AviadoBio
Founded Year 2019
Location United Kingdom London, United Kingdom
Employees 73
Industries Biotechnology, Health Care
Funding Stage Corporate Round
Social

BounceWatch is an independent company data service, not affiliated with AviadoBio. To contact AviadoBio, visit aviadobio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AviadoBio compare?

A PDF of AviadoBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AviadoBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AviadoBio

AviadoBio, founded in 2019 and headquartered in the United Kingdom, is making waves in the biotech industry with its mission to revolutionize gene therapy for neurodegenerative disorders, focusing on conditions like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

With a strong foundation in groundbreaking science originating from King’s College London and the UK Dementia Research Institute, AviadoBio has crafted a suite of proprietary gene therapy platforms that target the brain with precision. Their unique, neuroanatomy-led approach aims not just to treat but to halt or even reverse the progression of neurodegenerative diseases.

Having secured a $20.00M Corporate Round investment in October 2024 led by Astellas Pharma, the company continues to demonstrate its potential by advancing its technologies towards life-changing therapies. Investors would be wise to consider AviadoBio as a promising venture in the nuanced field of healthcare and biotechnology.

Business keywords: Gene Therapy, Neurodegenerative Disorders, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Precision Medicine, Neuroscience, Biotechnology Platforms, Drug Delivery Technology, Therapeutic Development, Research and Development, King’s College London, UK Dementia Research Institute, Life Sciences, Neuroanatomy-led Approaches, Innovative Therapies

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate Round $20.00M 1
Astellas Pharma
08 Oct 2024
Series A £58.60M 8
New Enterprise Associates Advent Life Sciences F-Prime Capital
New Enterprise Associates, Advent Life Sciences +6
02 Dec 2021
Seed Round £12.00M 2
Advent Life Sciences LifeArc
Advent Life Sciences, LifeArc
01 Jan 2020

AviadoBio Alternatives & Competitors

View All Alternatives
AviadoBio vs
Kineta (Reverse Merger With Yumanity Therapeutics)
Kineta (Reverse Merger With Yumanity Therapeutics)

Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfolding.

Venture round
Biotechnology, Health Care
Compare AviadoBio vs Kineta (Reverse Merger With Yumanity Therapeutics)
AviadoBio vs
Corlieve Therapeutics
Corlieve Therapeutics France

At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurologic...

Seed
1 employees
Biotechnology, Health Care
Compare AviadoBio vs Corlieve Therapeutics
AviadoBio vs
Nephrogen
Nephrogen United States

Curative gene therapies for kidney diseases

6 employees
Biotechnology, Health Care
Also compare with: AviadoBio vs QurAlis QurAlis View all alternatives

FAQ About AviadoBio

A revolution in gene therapy for neurodegenerative disorders.
AviadoBio was founded in 2019.
AviadoBio is headquartered in London, United Kingdom.
AviadoBio operates in Biotechnology and Health Care. Its work centres on Gene Therapy, Neurodegenerative Disorders, Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.
AviadoBio has approximately 73 employees.
AviadoBio has completed 3 funding rounds, raising a total of $90.60M. The latest funding stage is Corporate Round.
Top alternatives and competitors to AviadoBio include Kineta (Reverse Merger With Yumanity Therapeutics), Corlieve Therapeutics, Nephrogen, Neumora, ProMIS™ Neurosciences, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AviadoBio and Kineta (Reverse Merger With Yumanity Therapeutics) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AviadoBio, https://bouncewatch.com/company/aviadobio, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout